At ICON, our passion for advancing new medicines and treatments is driven by deeply personal stories that connect us to our mission. MyWhy is our platform to share these stories - stories that inspire, give us purpose, and foster growth. Our latest episode features our colleagues sharing their stories and reminding us how vital our work is to improving patients and their family’s lives.
Über uns
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
External link for ICON plc
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 10.001+ Mitarbeiter
- Hauptsitz
- Dublin
- Typ
- Öffentliches Unternehmen
- Spezialitäten
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs, and Global Patient Insights & Engagement
Standorte
Employees at ICON plc
Aktualisierungen
-
This 17 – 18 September you will have the opportunity to hear ICON experts unveil the latest innovations to modernize clinical trials. Join us at the Loews Philadelphia Hotel . https://ow.ly/J3Ur50SZ7YB
-
-
ICON is strengthening communities and increasing diversity in STEM by partnering with Trinity College Dublin, University of Limerick in Ireland and Thurgood Marshall College Fund in the US to provide scholarships for STEM course students. Learn more in the ICON Cares report: https://ow.ly/27lr50T8oui #ICONCares #DIB #EqualOpportunities #STEM #SDG10 #SDG4
-
-
For any new combination vaccine to be adopted, public health decision makers rely on health technology assessments to systematically assess the impact of introducing a new health technology from a multidisciplinary perspective. Discover more. https://ow.ly/kPtz50SXxzh
-
-
Our ISO 18587 certification helps ensure consistency and quality in the post-editing process, fostering trust and confidence in machine-translated content across various industries and applications. Read our blog on machine translation and how to ensure best practices in post-editing. https://ow.ly/hfqy50SXxeZ
-
-
Join us on 12 September 2024, for an insightful session on adapting and applying risk management plans (RMPs) effectively. Learn how to leverage digital tools and platforms to enhance RMP monitoring and implementation. Register for the webinar. https://ow.ly/4E7X50SE81V #Pharma #PatientSafety #RegulatoryAffairs #Webinar
-
-
As Immunization Awareness Month concludes, Ethan Taylor, Clinical Trial Manager at ICON PLC, shares his passion for working in the Vaccines and Infectious Diseases team and why this work is so important to him. Why not view our Clinical Trial Management opportunities available at ICON: https://ow.ly/kvAy50T7KLl
-
-
We're excited to be exhibiting at RAPS Convergence 2024, Long Beach, California Sept 17-19th. If you are planning on visiting, drop by Booth 1032 and meet our team of regulatory experts. https://ow.ly/xM5F50T6k7m Meet the team: Jamie Harris, MPH, RAC, Crystal Isgro, Gaelle Richer, Venkat Sunkara, Wendy DeSpain #RAPSConvergence #regulatoryaffairs #regulatory #regulatorycompliance #pharma #biotech #clinicaltrials #medicaldevices
-
-
In this PM360 article, Rebecca Rozich, Client Engagement & Medical Strategy Director at ICON, recommends, when measuring the effect of company campaigns, considering the valuable information captured through direct engagement and scientific exchange with key stakeholders. Discover more expert insights. https://ow.ly/ypoE50SZgcb
-
-
In this webinar ICON experts discuss considerations for Oligonucleotide therapeutics in CMC, including the critical quality attributes (CQAs) and critical process parameters (CPPs) in oligonucleotide drug product development, key aspects of manufacturing, stability, and scalability, and guidance on setting and meeting specifications to ensure quality and compliance when progressing into early phase studies. Register here: https://ow.ly/YeAg50SMUv7
-